Logo image of KYTX

KYVERNA THERAPEUTICS INC (KYTX) Stock Fundamental Analysis

USA - NASDAQ:KYTX - US5019761049 - Common Stock

6.97 USD
+0.22 (+3.26%)
Last: 10/31/2025, 8:00:02 PM
7.05 USD
+0.08 (+1.15%)
After Hours: 10/31/2025, 8:00:02 PM
Fundamental Rating

1

KYTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of KYTX is average, but there are quite some concerns on its profitability. KYTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KYTX had negative earnings in the past year.
KYTX had a negative operating cash flow in the past year.
KYTX Yearly Net Income VS EBIT VS OCF VS FCFKYTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -70.06%, KYTX is doing worse than 61.80% of the companies in the same industry.
With a Return On Equity value of -86.07%, KYTX perfoms like the industry average, outperforming 50.19% of the companies in the same industry.
Industry RankSector Rank
ROA -70.06%
ROE -86.07%
ROIC N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYTX Yearly ROA, ROE, ROICKYTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

KYTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYTX Yearly Profit, Operating, Gross MarginsKYTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, KYTX has more shares outstanding
Compared to 1 year ago, KYTX has an improved debt to assets ratio.
KYTX Yearly Shares OutstandingKYTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
KYTX Yearly Total Debt VS Total AssetsKYTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

KYTX has an Altman-Z score of 0.55. This is a bad value and indicates that KYTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KYTX (0.55) is better than 60.86% of its industry peers.
KYTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, KYTX perfoms like the industry average, outperforming 50.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.55
ROIC/WACCN/A
WACCN/A
KYTX Yearly LT Debt VS Equity VS FCFKYTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

KYTX has a Current Ratio of 5.39. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.39, KYTX is in line with its industry, outperforming 58.99% of the companies in the same industry.
KYTX has a Quick Ratio of 5.39. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
KYTX's Quick ratio of 5.39 is fine compared to the rest of the industry. KYTX outperforms 60.11% of its industry peers.
Industry RankSector Rank
Current Ratio 5.39
Quick Ratio 5.39
KYTX Yearly Current Assets VS Current LiabilitesKYTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

KYTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.25%.
EPS 1Y (TTM)-37.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KYTX will show a decrease in Earnings Per Share. The EPS will decrease by -1.61% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.17%
EPS Next 2Y-2.15%
EPS Next 3Y-3.51%
EPS Next 5Y-1.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KYTX Yearly Revenue VS EstimatesKYTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
KYTX Yearly EPS VS EstimatesKYTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KYTX. In the last year negative earnings were reported.
Also next year KYTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYTX Price Earnings VS Forward Price EarningsKYTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYTX Per share dataKYTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as KYTX's earnings are expected to decrease with -3.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.15%
EPS Next 3Y-3.51%

More info and screens

0

5. Dividend

5.1 Amount

KYTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYVERNA THERAPEUTICS INC

NASDAQ:KYTX (10/31/2025, 8:00:02 PM)

After market: 7.05 +0.08 (+1.15%)

6.97

+0.22 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-12 2025-11-12
Inst Owners63.86%
Inst Owner Change-13.36%
Ins Owners1.29%
Ins Owner Change2.25%
Market Cap301.45M
Revenue(TTM)N/A
Net Income(TTM)-158697000
Analysts85
Price Target23.46 (236.59%)
Short Float %4.15%
Short Ratio2.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.08%
Min EPS beat(2)8.85%
Max EPS beat(2)9.3%
EPS beat(4)3
Avg EPS beat(4)3.93%
Min EPS beat(4)-2.95%
Max EPS beat(4)9.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.37%
PT rev (3m)33.72%
EPS NQ rev (1m)-3.19%
EPS NQ rev (3m)-6.19%
EPS NY rev (1m)2.48%
EPS NY rev (3m)-1.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-3.68
EYN/A
EPS(NY)-3.62
Fwd EYN/A
FCF(TTM)-3.28
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS0
BVpS4.26
TBVpS4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.06%
ROE -86.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.39
Quick Ratio 5.39
Altman-Z 0.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.78%
EPS Next Y-9.17%
EPS Next 2Y-2.15%
EPS Next 3Y-3.51%
EPS Next 5Y-1.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-37.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.62%
EBIT Next 3Y-25.97%
EBIT Next 5YN/A
FCF growth 1Y-119.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.99%
OCF growth 3YN/A
OCF growth 5YN/A

KYVERNA THERAPEUTICS INC / KYTX FAQ

What is the fundamental rating for KYTX stock?

ChartMill assigns a fundamental rating of 1 / 10 to KYTX.


Can you provide the valuation status for KYVERNA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to KYVERNA THERAPEUTICS INC (KYTX). This can be considered as Overvalued.


Can you provide the profitability details for KYVERNA THERAPEUTICS INC?

KYVERNA THERAPEUTICS INC (KYTX) has a profitability rating of 0 / 10.